Why do longs continue to accumulate? Here's a few of the reasons:


WELCOME
PRESS RELEASES
EVENTS AND PRESENTATIONS
BLOG
EMAIL ALERTS

PRESS RELEASES
Year: All Years
All Years
2018
2017
2016
2015
2014
2013
2012
2011
2010
Category: All Categories
All Categories
Brilacidin
Kevetrin
Corporate
Prurisol
Filter

Search
October 24, 2018
INNOVATION PHARMACEUTICALS GRANTED END-OF-PHASE 2 MEETING

October 22, 2018
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON KEVETRIN PROGRAM; BRIDGING TOXICOLOGY EFFORTS AIMED AT DEVELOPING AN ORAL P53 ANTI-CANCER DRUG CANDIDATE

October 12, 2018
INNOVATION PHARMACEUTICALS BRILACIDIN AS A NOVEL INHIBITOR OF PHOSPHODIESTERASE 4 (PDE4) SUPPORTS ITS POTENTIAL TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES

October 9, 2018
INNOVATION PHARMACEUTICALS SECURES UP TO $10 MILLION IN ADDITIONAL FINANCING TO ADVANCE CLINICAL PIPELINE

September 24, 2018
INNOVATION PHARMACEUTICALS PROVIDES A COMPARATIVE PERSPECTIVE ON BRILACIDIN’S POTENTIAL TO UNLOCK THE ORAL MUCOSITIS MARKET: PHARMA INDUSTRY ATTACKS SEVERE PAIN AND SUFFERING DUE TO CANCER TREATMENTS

September 20, 2018
INNOVATION PHARMACEUTICALS PROVIDES CORPORATE UPDATE HIGHLIGHTING UPCOMING MILESTONES AND EVENTS

September 5, 2018
INNOVATION PHARMACEUTICALS TO PRESENT BRILACIDIN FOR INFLAMMATORY BOWEL DISEASE AT INAUGURAL “IBD INNOVATE 2018” CONFERENCE HOSTED BY THE CROHN’S & COLITIS FOUNDATION

July 17, 2018
INNOVATION PHARMACEUTICALS SIGNS DRUG PRODUCT MANUFACTURING CONTRACT WITH CORERX TO FORMULATE AND PACKAGE BRILACIDIN FOR ORAL MUCOSITIS IN SACHET FORM
Go IPIX!!!